Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE + GP chemotherapy + tislelizumab for first-line advanced or unresectable intrahepatic cholangiocarcinoma
ChiCTR2200059948Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2200059948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059948.